Skip to content

Advertisement

  • Poster presentation
  • Open Access

German evidence and consensus based guidelines 2010 for the treatment of juvenile idiopathic arthritis (JIA)

  • 1Email author,
  • 2,
  • 3,
  • 4,
  • 5,
  • 6,
  • 7,
  • 8,
  • 9,
  • 7,
  • 10,
  • 11,
  • 12,
  • 13,
  • 14,
  • 15,
  • 16,
  • 13,
  • 17 and
  • 1
Pediatric Rheumatology20119 (Suppl 1) :P181

https://doi.org/10.1186/1546-0096-9-S1-P181

  • Published:

Keywords

  • Juvenile Idiopathic Arthritis
  • Clinical Practice Guideline
  • Biologic Agent
  • Scientific Society
  • Consensus Statement

Background

To improve the quality of care for patients with JIA, standardization of treatment is mandatory. We present a clinical practice guideline (CPG) for the treatment of JIA. It is based on the existing CPG of 2005* and 2008# (*published as book chapter; #peer reviewed publication: Clinical Research and Practice in Paediatrics 2008; 220: 392 - 402).

Methods

We performed a systematic literature analysis in PubMed (deadline: 15th January 2010, terms "juvenile idiopathic (rheumatoid) arthritis", "therapy", limits: “humans”, “published in the last 3 years”, “all child 0-18 years”, “clinical trial”) and evaluated relevant studies for quality of methodology. A formal consensus process, i.e. Nominal group technique and Delphi method, was conducted at three moderated consensus conferences at Düsseldorf or Krefeld (Germany) on May 9th, 2007, August 1st, 2007 and January 15th, 2010. Conferences were attended by 95% of the representatives who had been nominated by their scientific society or organizations.

Results

15 consensus statements and key notes regarding drug therapy, symptomatic and surgical management of JIA were compiled and judged strictly by the criteria of Evidence-Based Medicine (presented on the poster).

Conclusions

Currently, we recommend that JIA is treated with NSAR followed by local GC and/ or MTX as first line treatment. Other interventions e. g. the role of biologic agents, physiotherapy, and arthroscopy are discussed strictly on the basis of literature available. Our CPG will require a frequent update, as the number of randomized trials is increasing and the new potential drugs will become available.

Authors’ Affiliations

(1)
HELIOS Children’s Hospital, Krefeld, Germany
(2)
German Federal Armed Forces central hospital, Koblenz, Germany
(3)
Rheumazentrum Oberammergau, Oberammergau, Germany
(4)
Olgahospital, Stuttgart, Germany
(5)
Klinikum Eilbeck, Hamburg, Germany
(6)
University Children’s Hospital, Muenster, Germany
(7)
St. Josef Stift, Sendenhorst, Germany
(8)
St. Franziskus Hospital, Münster, Germany
(9)
Asklepios Children’s Hospital, St. Augustin, Germany
(10)
Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Marburg, Germany
(11)
University Department of Orthopaedics, Duesseldorf, Germany
(12)
Deutsche Rheuma Liga e.V., Bonn, Germany
(13)
German Centre for Paediatric and Adolescent Rheumatology, Garmisch Partenkirchen, Germany
(14)
University Department of Endocrinology, Diabetology and Rheumatology, Duesseldorf, Germany
(15)
Berlin-Schoeneberg, Germany
(16)
University Department of Surgical Research, Marburg, Germany
(17)
University Children’s Hospital, Aachen, Germany

Copyright

Advertisement